Research ArticleClinical Investigation
Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
Kerstin Michalski, Claudius Klein, Tonio Brüggemann, Philipp T. Meyer, Cordula A. Jilg and Juri Ruf
Journal of Nuclear Medicine December 2021, 62 (12) 1741-1746; DOI: https://doi.org/10.2967/jnumed.120.260836
Kerstin Michalski
1Department of Nuclear Medicine, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany; and
Claudius Klein
1Department of Nuclear Medicine, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany; and
Tonio Brüggemann
1Department of Nuclear Medicine, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany; and
Philipp T. Meyer
1Department of Nuclear Medicine, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany; and
Cordula A. Jilg
2Department of Urology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany
Juri Ruf
1Department of Nuclear Medicine, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue 12
December 1, 2021
Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
Kerstin Michalski, Claudius Klein, Tonio Brüggemann, Philipp T. Meyer, Cordula A. Jilg, Juri Ruf
Journal of Nuclear Medicine Dec 2021, 62 (12) 1741-1746; DOI: 10.2967/jnumed.120.260836
Jump to section
Related Articles
Cited By...
- PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
- Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
- 68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer
- A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0